TED Hair Restoration: The Candidacy Framework for Knowing When It Works and When Surgery Is Needed
Introduction: The Question That Actually Matters
Most people searching for “TED hair restoration” have already seen the marketing. They have scrolled past before-and-after photos, read clinic pages promising needle-free regrowth, and possibly received a promotional email from a local med-spa. They are not asking how TED works. They want a more practical answer: whether TED is right for their situation, or whether surgery is the better path.
This article answers that question. It is a candidacy framework, not a mechanism explainer. Readers who want a technical breakdown of sonophoresis and the Alma TED device can find it in Charles Medical Group’s companion article on Alma TED. This piece focuses on who benefits from TED, who does not, and how to tell the difference.
The framework comes from a practice with no financial reason to oversell non-surgical treatment. Charles Medical Group has worked exclusively in hair restoration since 1999. Dr. Glenn Charles has performed more than 15,000 procedures, and the practice offers the full range of options: Propecia, Rogaine, LaserCap therapy, Alma TED, scalp micropigmentation, FUE, FUT, and ARTAS robotic restoration. A provider that offers every option has no reason to push any single one, which makes its recommendation more useful than advice from a clinic that sells only one treatment.
What Alma TED Is, Briefly (For Context, Not Explanation)
Alma TED (TransEpidermal Delivery) is a needle-free device. It uses acoustic sound waves and air pressure, a process called sonophoresis, to push a proprietary topical serum called the TED+ Hair Care Formula through the skin barrier and into the scalp. Sessions typically last 20 to 30 minutes and involve no needles, no numbing, no bleeding, and no downtime. Most patients need multiple sessions before they see visible results.
For the full mechanism breakdown, readers should see the companion article on this site. Knowing what TED is matters less than knowing who it is actually for, and the rest of this article addresses that.
FDA Class II Clearance: What It Actually Means, and What It Does Not
Many clinic pages describe Alma TED as “FDA-cleared” and leave it there. The phrase is accurate, but it needs context.
Alma TED went through the 510(k) Class II clearance pathway. Under this pathway, a manufacturer shows that a device is substantially equivalent to devices already on the market and is safe for its stated use. This is different from the full FDA approval process for drugs, which requires the manufacturer to prove efficacy through rigorous clinical trials.
The FDA clearance letter (K251684) states that the Alma TED+ System is indicated to treat androgenetic alopecia and promote hair growth in females with Ludwig pattern loss and males with male pattern loss. That wording sets a clear boundary. The clearance does not extend to scarring alopecias or alopecia areata, a distinction most marketing pages leave out.
The practical takeaway is this:
- “FDA-cleared” as a trust badge suggests the device is proven to work for anyone losing hair.
- What the clearance actually permits is a defined indication: pattern hair loss in men and women, using a device shown to be safe and substantially equivalent to existing technology.
Clearance confirms safety and the intended category of use. It does not mean the device can regrow hair where follicles no longer exist.
The Evidence Base: What the Studies Show and Where They Fall Short
The early data on Alma TED is encouraging. Patients should still read it carefully.
Manufacturer-sponsored findings include:
- N=50 study (presented at AAD 2023): 96% of patients noticed increased hair growth after two sessions over one month. Separate reporting from this data set cites 98% reduced shedding, 89% visible density improvement, and 100% patient satisfaction after three treatments.
- N=31 study (mostly female participants): Three treatments produced a 23% increase in hair density at one month and 31% at six months. Researchers observed early and sustained terminalization across treated areas and reported no pain or adverse events.
- A six-month dual-center white paper: Overall density improved 26%, vertex density improved 45%, and one case showed a 108% improvement at the left temple. Results varied significantly by case and treatment zone.
The limitations are real. The sample sizes are small, and the studies were sponsored by or affiliated with the manufacturer. As of 2026, no large-scale independent randomized controlled trials of Alma TED have been published.
The underlying science does have independent support, however. A 2020 study published in Scientific Reports found that dual-frequency ultrasound-mediated microbubble cavitation significantly enhanced transdermal minoxidil delivery in both in vitro and in vivo models, and improved hair growth efficacy compared with single-frequency ultrasound. That research did not test the Alma-branded device, but it supports the principle the device relies on.
The honest summary: TED has a biologically plausible mechanism, independent research supporting that mechanism, and promising early device-specific data. It has not yet reached the level of evidence that RCT-backed therapies have.
Why Candidacy Is the Real Variable (Not Just “Does TED Work”)
Asking “Does TED work?” misses the point. The better question is: work on what?
TED has a firm biological limit. It cannot create new follicles or restore hair where none remain. It can only support follicles that are still present, including those that are miniaturizing. A thinning area with living follicles is a reasonable target. A smooth, bald area is not.
On the surgical side, the key threshold is donor density. ISHRS FUE clinical practice guidelines call for densitometry to evaluate the donor scalp. Normal density ranges from 60 to 100 follicular units per square centimeter (FU/cm²), and grafts should come from the safe donor area so results are permanent. Common clinical benchmarks put optimal transplant candidacy above roughly 80 FU/cm². Density below 40 FU/cm² severely limits or eliminates surgical options.
This principle applies in both directions. TED cannot make up for insufficient donor supply, and no surgeon can responsibly recommend a transplant without first assessing stage and density. The three-bucket framework below turns these clinical facts into practical guidance for patients.
The Three-Bucket Candidacy Framework
This framework reflects a surgical practice’s view of the full treatment continuum, not the sales funnel of a single technology. Most patients fall into one of three groups.
Bucket 1: Early or Diffuse Thinners Not Yet Surgical Candidates
Profile: Early miniaturization, diffuse thinning, or donor and recipient characteristics that do not yet meet surgical thresholds.
TED is a logical first step for this group. The follicles are still present and viable, so delivering the topical formula more effectively has a plausible benefit. These patients are often also candidates for Propecia, Rogaine, and LaserCap therapy, and TED works best layered into that regimen rather than used alone.
Monitoring is essential. This is not a permanent category. Regular evaluation shows whether thinning stabilizes, improves, or progresses toward surgical territory.
Bucket 2: Surgical Candidates Who Want to Try Non-Surgical First, or Are in Maintenance Mode
This bucket includes two groups:
- Patients who qualify for FUE or FUT but prefer to try non-surgical options first. This is a legitimate choice. TED involves no downtime and no needles, and it lets patients try a reversible option before committing to surgery.
- Post-transplant patients protecting their native hair. Transplanted grafts are permanent, but the native hair around them can keep miniaturizing. TED, often combined with finasteride or minoxidil, can be part of a long-term plan to protect that hair.
Realistic expectations matter. TED results are not permanent. Keeping them requires maintenance sessions or combination therapy, so this bucket calls for an ongoing plan rather than a one-time treatment.
Neutral advice matters most in this bucket. A practice that offers both pathways has no incentive to steer a patient one way or the other.
Bucket 3: Advanced Norwood/Ludwig Patients Where TED Cannot Substitute for Transplant
Profile: Advanced Norwood classes with significant crown or vertex loss and extensive frontal recession, or higher Ludwig stages in women with substantial diffuse central thinning.
TED cannot help in zones of complete follicular loss. It cannot create follicles, and where none remain, the TED+ formula has nothing to stimulate.
The risk is that this group gets sold TED anyway. The consequences include delayed treatment, false hope, and lost time while hair loss continues to progress.
For these patients, FUE, FUT (strip), and ARTAS robotic restoration are the only tools that can restore coverage. Graft counts and surgical planning depend on each patient’s donor supply and area of loss. A provider that offers only TED profits from recommending it at every stage. A surgical practice has no such incentive and can state plainly when a transplant is the only real option.
Why This Recommendation Can Be Trusted: The Credibility Gap Most Providers Cannot Close
Med-spas and clinics that offer only TED, only PRP, or only topical products have a built-in incentive to classify as many patients as possible as candidates. This does not make them dishonest, but it does shape their recommendations.
Charles Medical Group works under a different structure. With more than 15,000 surgical procedures and an exclusive focus on hair restoration since 1999, the practice has no incentive to recommend surgery simply because TED underperformed, nor does it recommend non-surgical care merely to fill treatment chairs.
Dr. Charles’s credentials cover the whole field, not one device. He is Past President of the American Board of Hair Restoration Surgery, a Fellow of the ISHRS, an annual faculty lecturer at ISHRS conferences, and the author and editor of Hair Transplantation and Hair Transplant 360.
Bucket placement happens through a complimentary one-on-one consultation that includes donor density evaluation and a custom treatment plan. The practice’s conservative, no-pressure approach reinforces this, with an emphasis on realistic expectations and transparent communication rather than upselling.
TED as Part of a Layered Plan, Not a Standalone Bet
TED is most defensible as one part of a combined plan. Common pairings include:
- Minoxidil (topical support)
- Finasteride (systemic DHT management)
- LaserCap / low-level laser therapy
- PRP
- Pre- and post-transplant adjunct care to support scalp health and native hair around a planned or completed procedure
This approach matches how the independent sonophoresis research frames ultrasound-enhanced delivery: as a way to make topical treatments more effective, not as a replacement for proven systemic or surgical interventions. A layered plan works best at a practice that can prescribe, administer, and surgically perform every tier of treatment in one place.
How Candidacy Is Determined: Finding the Right Bucket
An honest candidacy evaluation includes four parts:
- Visual staging using the Norwood (men) or Ludwig (women) scale
- Donor density assessment to determine surgical feasibility
- A discussion of goals and timeline, including tolerance for downtime and long-term maintenance
- A medical history review to rule out non-androgenetic causes that fall outside TED’s cleared indication
Self-diagnosis from photos or online quizzes is unreliable. Lighting, hair length, and camera angles can make hair look thinner or fuller than it is, and donor density cannot be measured from a selfie. A specialist consultation provides an accurate assessment.
For out-of-state or international patients weighing TED against surgery before they travel, Charles Medical Group offers virtual consultations via FaceTime and Skype. The evaluation is complimentary and carries no commitment. Its purpose is accurate bucket placement, not a sales pitch.
Conclusion
Alma TED is a legitimate, FDA Class II–cleared, needle-free treatment. Its mechanism is biologically plausible and partly supported by independent research. Its value, however, depends on where a patient falls in the candidacy spectrum.
- Bucket 1: Early or diffuse thinners with viable follicles who are not yet surgical candidates
- Bucket 2: Surgical candidates trying non-surgical options first, or post-transplant patients protecting native hair
- Bucket 3: Advanced-stage patients who need surgery, because TED cannot create follicles that no longer exist
Candid, stage-specific guidance like this is only credible from a practice that offers every option on the spectrum and has no financial reason to favor any of them.
Find the Right Treatment Path
Charles Medical Group invites patients to schedule a complimentary consultation with Dr. Charles and his team for an honest, personalized candidacy assessment.
- Phone: 866-395-5544
- Locations: 200 Glades Rd #2, Boca Raton, FL 33432, and Brickell, Miami
- Virtual consultations: Available via FaceTime and Skype for out-of-state and international patients
With more than 25 years of exclusive focus on hair restoration, the practice offers no-pressure, transparent guidance. Patients leave knowing which bucket they are in and which path makes sense for them.



